ausstehenden Wandelanleihen mit Fälligkeit 2026 an
Finanz und Wirtschaft DocMorris AG / Schlagwort(e): Anleihe
DocMorris kündigt Beginn der Rückkaufangebotsfrist für die ausstehenden
Wandelanleihen mit Fälligkeit 2026 an
06.11.2025 / 07:00 CET/CEST
------------------------------------------------------------
Frauenfeld, 6. November 2025
Medienmitteilung
DocMorris kündigt Beginn der Rückkaufangebotsfrist für die ausstehenden
Wandelanleihen mit Fälligkeit 2026 an
Nach der Veröffentlichung des Rückkaufinserats am 22. Oktober 2025 und dem Ende
der Karenzfrist kündigt DocMorris den Beginn der Rückkaufangebotsfrist für die
ausstehenden Wandelanleihen mit Fälligkeit 2026 an. Der Angebotspreis für jede
der ausstehenden Wandelanleihen mit Fälligkeit 2026 beträgt CHF 1'035.00 pro
Anleihe, entsprechend 103.50% des Nennwerts, zuzüglich aufgelaufener und nicht
bezahlter Zinsen.
Die Rückkaufangebotsfrist beginnt heute und endet voraussichtlich am 12.
November 2025 um 16:00 Uhr MEZ. Die Abwicklung des Rückkaufangebots wird
voraussichtlich am 17. November 2025 erfolgen. Die Anleihen sind an der SIX
Swiss Exchange kotiert und gehandelt (ISIN: CH1210198169; SSN: A3K86S).
Diese Pressemitteilung stellt kein Angebot zum Rückkauf der ausstehenden
Wandelanleihen mit Fälligkeit 2026 dar, sondern gibt lediglich die wichtigsten
Bedingungen des geplanten Rückkaufangebots bekannt. Das Rückkaufangebot erfolgt
ausschliesslich auf der Grundlage des am 22. Oktober 2025 veröffentlichten
Rückkaufinserats in Übereinstimmung mit den schweizerischen Regeln über
Rückkaufangebote.
Kontakt für Analysten und Investoren
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
E-Mail: [email protected], Telefon: 41 52 560 58 10
Kontakt für Medien
Torben Bonnke, Director Communications
E-Mail: [email protected], Telefon: +49 171 864 888 1
Agenda
20. Januar 2026 Umsatz 2025
19. März 2026 Jahresergebnis 2025 und Ausblick 2026 (Conference Call/Webcast)
16. April 2026 Q1/2026 Trading update
12. Mai 2026 Ordentliche Generalversammlung, Zürich
DocMorris
Die Schweizer DocMorris AG ist ein führendes Unternehmen in den Bereichen
Online-Apotheke, Telemedizin und Marktplatz mit starken Marken in Deutschland
und weiteren europäischen Ländern. Die Belieferung erfolgt hauptsächlich aus
dem hochautomatisierten Logistikzentrum im niederländischen Heerlen. TeleClinic
ist Deutschlands grösste Telemedizinplattform, die Patienten mit mehr als 5'000
Ärzten verbindet. In Südeuropa betreibt DocMorris führende Marktplätze für
Gesundheits- und Pflegeprodukte. Mit ihrem breiten Spektrum an Produkten und
Dienstleistungen verfolgt DocMorris die Vision, der führende digitale
Gesundheitsbegleiter zu werden, bei dem Menschen ihre Gesundheit mit einem
Klick managen können. Im Jahr 2024 erzielten rund 1'600 Mitarbeiter in
Deutschland, den Niederlanden, Spanien, Frankreich, Portugal und der Schweiz
mit über 10 Millionen aktiven Kunden einen Aussenumsatz von CHF 1'085 Mio. Die
Aktien der DocMorris AG sind an der SIX Swiss Exchange kotiert (Valor 4261528,
ISIN CH0042615283, Ticker DOCM). Weitere Informationen unter
corporate.docmorris.com.
Disclaimer
THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE
RESPONSIBILITY OF DOCMORRIS AG (THE "COMPANY") AND DOCMORRIS FINANCE B.V. (THE
"ISSUER"). THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND
PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE
PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS
ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.
THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR
PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA, CANADA,
ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH
OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE
THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED
OR PROHIBITED BY LAW,
THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE
DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.
THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN
JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER
INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE
SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE
A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE
COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN
PARTICULAR, THE SECURITIES OF THE COMPANY AND THE ISSUER REFERRED TO HEREIN MAY
NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US
SECURITIES ACT OF 1933 (THE "SECURITIES ACT") OR OFFERED IN A TRANSACTION
EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED
UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA,
CANADA OR JAPAN. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO
HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR
FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN "OFFSHORE TRANSACTION" IN
ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT OR FOR THE ACCOUNT OR
BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN.
THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO THE SWISS FEDERAL
ACT ON FINANCIAL SERVICES.
IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM
(EACH, A "RELEVANT STATE"), THIS ANNOUNCEMENT AND ANY OFFER IF MADE
SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN
THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129)
("QUALIFIED INVESTORS"). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED
EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN
MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL
SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE
"ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND
(III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, AND ANY INVESTMENT
ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH PERSONS AND IT
SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.
THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE,
"FORWARD-LOOKING STATEMENTS". THESE FORWARD-LOOKING STATEMENTS MAY BE
IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS
"BELIEVES", "ESTIMATES", "PLANS", "PROJECTS", "ANTICIPATES", "EXPECTS",
"INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE, THEIR NEGATIVE OR OTHER
VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS,
OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY
AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY FORWARD-LOOKING
STATEMENTS REFLECT THE ISSUER’S OR THE COMPANY’S CURRENT VIEW WITH RESPECT TO
FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER
RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP’S BUSINESS, RESULTS
OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES.
FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE. EACH OF THE
ISSUER, THE COMPANY, THE JOINT BOOKRUNNERS AND THEIR RESPECTIVE AFFILIATES
EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE
ANY FORWARD LOOKING STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A
RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.
THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR NOTICE WITHIN
THE MEANING OF THE ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL SERVICES
ACT OR UNDER ANY OTHER LAW OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE
APPLICABLE LISTING RULES OF ANY STOCK EXCHANGE. ANY PURCHASE OF BONDS OF THE
ISSUER IN THE PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF THE
INFORMATION CONTAINED IN THE FINAL PROSPECTUS TO BE ISSUED BY THE ISSUER IN
CONNECTION WITH THE OFFERING. ANY PURCHASE OF SHARES OF THE COMPANY IN THE
PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF PUBLICLY AVAILABLE
INFORMATION. THE INFORMATION IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE THE
JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER AND THE COMPANY AND NO-ONE
ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER PERSON AS
THEIR RESPECTIVE CLIENTS IN RELATION TO THE OFFERING AND WILL NOT BE
RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE COMPANY FOR PROVIDING THE
PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN
RELATION TO THE OFFERING, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION,
ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.
IN CONNECTION WITH THE OFFERING OF THE BONDS AND THE SHARES, THE JOINT
BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A PORTION OF THE SECURITIES
IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY, MAY RETAIN,
PURCHASE, SELL, OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH SECURITIES AND OTHER
SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED INVESTMENTS IN CONNECTION
WITH THE OFFERINGS OR OTHERWISE. ACCORDINGLY, REFERENCES IN THE PROSPECTUS
RELATED TO THE BONDS, ONCE PUBLISHED, BEING ISSUED, OFFERED, SUBSCRIBED,
ACQUIRED, PLACED OR OTHERWISE DEALT IN SHOULD BE READ AS INCLUDING ANY ISSUE OR
OFFER TO, OR SUBSCRIPTION, ACQUISITION, PLACING OR DEALING BY THE JOINT
BOOKRUNNERS AND ANY OF THEIR AFFILIATES ACTING IN SUCH CAPACITY. IN ADDITION,
THE JOINT BOOKRUNNERS, AND ANY OF THEIR AFFILIATES MAY ENTER INTO FINANCING
ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH
INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR
AFFILIATES MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES OF THE
ISSUER OR THE COMPANY. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE
EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH
ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.
NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS,
EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR LIABILITY
WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS
TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT
(OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE ANNOUNCEMENT) OR ANY
OTHER INFORMATION RELATING TO THE ISSUER OR THE COMPANY, THEIR SUBSIDIARIES OR
ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELECTRONIC FORM,
AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING
FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN
CONNECTION THEREWITH.
NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS
OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER TO
ACQUIRE SECURITIES IN ANY JURISDICTION. ANY INVESTOR SHOULD MAKE HIS INVESTMENT
DECISION FOR THE PURCHASE OF THE SHARES ON PUBLICLY AVAILABLE INFORMATION AND
FOR THE PURCHASE OF THE BONDS SOLELY ON THE BASIS OF THE INFORMATION THAT IS
CONTAINED IN THE PROSPECTUS (THE "PROSPECTUS") PUBLISHED BY THE COMPANY AND THE
ISSUER IN CONNECTION WITH THE OFFERING AND ADMISSION TO TRADING AND LISTING OF
THE BONDS TO BE ISSUED BY THE ISSUER AS DESCRIBED IN THE PROSPECTUS ON THE SIX
SWISS EXCHANGE. COPIES OF THE PROSPECTUS ARE AVAILABLE FREE OF CHARGE AT [UBS
AG, PROSPECTUS LIBRARY, P.O. BOX, CH-8098 ZURICH (TELEPHONE NUMBER: +41 (0)44
239 47 03, FACSIMILE: +41 (0)44 239 69 14 OR EMAIL: [email protected]),
DURING REGULAR BUSINESS HOURS]
------------------------------------------------------------
Ende der Medienmitteilungen
Originalinhalt anzeigen: EQS News
------------------------------------------------------------
Sprache: Deutsch
Unternehmen: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Schweiz
ISIN: CH0042615283
Börsen: SIX Swiss Exchange
EQS News ID: 2224592
Ende der Mitteilung EQS News-Service
------------------------------------------------------------
2224592 06.11.2025 CET/CEST